The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
Abstract
A series of alterations in the cellular genome affecting the expression or function of genes controlling cell growth and differentiation is considered to be the main cause of cancer. These mutational events include activation of oncogenes and inactivation of tumor suppressor genes. The elucidation of human cancer at the molecular level allows the design of rational, mechanism-based therapeutic agents that antagonize the specific activity of biochemical processes that are essential to the malignant phenotype of cancer cells. Because the frequency of RAS mutations is among the highest for any gene in human cancers, development of inhibitors of the Ras–mitogen-activated protein kinase pathway as potential anticancer agents is a very promising pharmacologic strategy. Inhibitors of Ras signaling have been shown to revert Ras-dependent transformation and cause regression of Ras-dependent tumors in animal models. The most promising new class of these potential cancer therapeutics are the farnesyltransferase inhibitors. The development of these compounds has been driven by the observation that oncogenic Ras function is dependent upon posttranslational modification, which enables membrane binding. In contrast to many conventional chemotherapeutics, farnesyltransferase inhibitors are remarkably specific and have been demonstrated to cause no gross systemic toxicity in animals. Some orally bioavailable inhibitors are presently being evaluated in phase II clinical trials. This review presents an overview on some inhibitors of the Ras signaling pathway, including their specificity and effectiveness in vivo. Because Ras signaling plays a crucial role in the pathogenesis of some hematologic malignancies, the potential therapeutic usefulness of these inhibitors is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 1,743
Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis
Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281805 · Cited by 1,717
Mitogen-Activated Protein Kinases: Specific Messages from Ubiquitous Messengers
Schaeffer, H. J., & Weber, M. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2435 · Cited by 1,600
Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
The Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Regulation of transcription by MAP kinase cascades
Treisman, R. (1996) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(96)80067-6 · Cited by 1,296
Organization and regulation of mitogen-activated protein kinase signaling pathways
Garrington, T. P., & Johnson, G. L. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80028-3 · Cited by 1,275
Coupling of the RAS-MAPK Pathway to Gene Activation by RSK2, a Growth Factor-Regulated CREB Kinase
Xing, J., Ginty, D. D., & Greenberg, M. E. (1996) · Science · doi:10.1126/science.273.5277.959 · Cited by 1,248
Golub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
The neurofibromatosis type 1 gene encodes a protein related to GAP
Xu, G., O'Connell, P., Viskochil, D., Cawthon, R., Robertson, M., Culver, M., Dunn, D., Stevens, J., Gesteland, R., White, R., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90024-9 · Cited by 1,095
G PROTEIN MECHANISMS: Insights from Structural Analysis
Sprang, S. R. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.639 · Cited by 1,065
The Primary Structure of MEK, a Protein Kinase that Phosphorylates the ERK Gene Product
Crews, C. M., Alessandrini, A., & Erikson, R. L. (1992) · Science · doi:10.1126/science.1411546 · Cited by 913
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
Nagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 872
The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias
Epstein, F. H., Kurzrock, R., Gutterman, J. U., & Talpaz, M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810133191506 · Cited by 837
Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides
Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J., & Brown, M. S. (1990) · Cell · doi:10.1016/0092-8674(90)90242-7 · Cited by 817
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Hallek, M., Leif Bergsagel, P., & Anderson, K. C. (1998) · Blood · doi:10.1182/blood.v91.1.3 · Cited by 752
Casey, P. J., & Seabra, M. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5289 · Cited by 716
Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation
Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S., & Der, C. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.6443 · Cited by 683
Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., & Marsters, J. C. (1993) · Science · doi:10.1126/science.8316834 · Cited by 630
Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki- ras
Shirasawa, S., Furuse, M., Yokoyama, N., & Sasazuki, T. (1993) · Science · doi:10.1126/science.8465203 · Cited by 620
Bollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T., et al. (1996) · Nature Genetics · doi:10.1038/ng0296-144 · Cited by 589
Sequence dependence of protein isoprenylation
Moores, S. L., Schaber, M. D., Mosser, S. D., Rands, E., O'Hara, M. B., Garsky, V. M., Marshall, M. S., Pompliano, D. L., & Gibbs, J. B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98729-6 · Cited by 580
DeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., & Lowy, D. R. (1992) · Cell · doi:10.1016/0092-8674(92)90407-4 · Cited by 580
Selective Inhibition of ras -Dependent Transformation by a Farnesyltransferase Inhibitor
Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., & Gibbs, J. B. (1993) · Science · doi:10.1126/science.8316833 · Cited by 579
Hunter, T. (1997) · Cell · doi:10.1016/s0092-8674(00)81872-3 · Cited by 550
K-ras is an essential gene in the mouse with partial functional overlap with N-ras
Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 545
Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., Desolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., et al. (1995) · Nature Medicine · doi:10.1038/nm0895-792 · Cited by 540
Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., & Der, C. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6403 · Cited by 540
Carpenter, C. L., & Cantley, L. C. (1996) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(96)80060-3 · Cited by 534
A role for Rho in Ras transformation
Qiu, R. G., Chen, J., McCormick, F., & Symons, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11781 · Cited by 533
The ins and outs of Raf kinases
Daum, G., Eisenmann-Tappe, I., Fries, H.-W., Troppmair, J., & Rapp, U. R. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90133-3 · Cited by 524
Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
Gibbs, J. B., Oliff, A., & Kohl, N. E. (1994) · Cell · doi:10.1016/0092-8674(94)90308-5 · Cited by 517
Marshall, C. J. (1996) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(96)80066-4 · Cited by 462
Ras C-terminal processing enzymes—New drug targets?
Gibbs, J. B. (1991) · Cell · doi:10.1016/0092-8674(91)90352-y · Cited by 454
Shannon, K. M., O'Connell, P., Martin, G. A., Paderanga, D., Olson, K., Dinndorf, P., & McCormick, F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300903 · Cited by 444
Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase kinase in vitro.
Posada, J., Yew, N., Ahn, N. G., Vande Woude, G. F., & Cooper, J. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.4.2546 · Cited by 410
Niemeyer, C. M., Aricò, M., Basso, G., Biondi, A., Rajnoldi, A. C., Creutzig, U., Haas, O. A., Harbott, J., Hasle, H., Kerndrup, G. B., et al. (1997) · PubMed · doi:10.1182/blood.v89.10.3534 · Cited by 406
Sepp‐Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, W. W., Oliff, A. I., & Rosen, N. X. (1995) · PubMed · Cited by 383
How receptor tyrosine kinases activate ras
Schlessinger, J. (1993) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(93)90031-h · Cited by 379
Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo
Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., & Garcia, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14093 · Cited by 368
Modulation of Ras and a-Factor Function by Carboxyl-Terminal Proteolysis
Boyartchuk, V. L., Ashby, M. N., & Rine, J. (1997) · Science · doi:10.1126/science.275.5307.1796 · Cited by 361
Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., & Sebti, S. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26802 · Cited by 361
Farr, C. J., Saiki, R. K., Erlich, H. A., McCormick, F., & Marshall, C. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.5.1629 · Cited by 356
K-Ras is essential for the development of the mouse embryo
Koera, K., Nakamura, K., Nakao, K., Miyoshi, J., Toyoshima, K., Hatta, T., Otani, H., Aiba, A., & Katsuki, M. (1997) · Oncogene · doi:10.1038/sj.onc.1201284 · Cited by 355
Khosravi-Far, R., White, M. A., Westwick, J. K., Solski, P. A., Chrzanowska-Wodnicka, M., Van Aelst, L., Wigler, M. H., & Der, C. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3923 · Cited by 343
Crystal Structure of Protein Farnesyltransferase at 2.25 Angstrom Resolution
Park, H.-W., Boduluri, S. R., Moomaw, J. F., Casey, P. J., & Beese, L. S. (1997) · Science · doi:10.1126/science.275.5307.1800 · Cited by 338
Post-translational modifications of p21rho proteins.
Adamson, P., Marshall, C. J., Hall, A., & Tilbrook, P. A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)88661-1 · Cited by 335
All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral
Bos, J. L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.23.6776 · Cited by 332
Zheng, C. F., & Guan, K. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82142-1 · Cited by 330
Oligomerization of the ABL Tyrosine Kinase by the Ets Protein TEL in Human Leukemia
Golub, T. R., Goga, A., Barker, G. F., Afar, D. E. H., McLaughlin, J., Bohlander, S. K., Rowley, J. D., Witte, O. N., & Gilliland, D. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4107 · Cited by 324
THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS
Gibbs, J. B., & Oliff, A. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.143 · Cited by 324
Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
Porter, A. C., & Vaillancourt, R. R. (1998) · Oncogene · doi:10.1038/sj.onc.1202171 · Cited by 320
MEKKs, GCKs, MLKs, PAKs, TAKs, and Tpls: upstream regulators of the c-Jun amino-terminal kinases?
Fanger, G. R., Gerwins, P., Widmann, C., Jarpe, M. B., & Johnson, G. L. (1997) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(97)80111-6 · Cited by 318
The dynamic role of palmitoylation in signal transduction
Milligan, G., Parenti, M., & Magee, A. I. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89004-0 · Cited by 313
Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase.
Reiss, Y., Stradley, S. J., Gierasch, L. M., Brown, M. S., & Goldstein, J. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.732 · Cited by 313
Liu, M., Bryant, M., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M. G., Ferrari, E., Nielsen, L. L., Prioli, N. A., et al. (1998) · PubMed · Cited by 309
Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase.
Salmeron, A., Ahmad, T. B., Carlile, G. W., Pappin, D., Narsimhan, R. P., & Ley, S. C. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00417.x · Cited by 300
Signal transduction from multiple Ras effectors
Katz, M. E., & McCormick, F. (1997) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(97)80112-8 · Cited by 299
DeSilva, D. R., Jones, E. A., Favata, M. F., Jaffee, B. D., Magolda, R. L., Trzaskos, J. M., & Scherle, P. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4175 · Cited by 295
Side, L., Taylor, B., Cayouette, M., Conner, E., Thompson, P., Luce, M., & Shannon, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706123362404 · Cited by 295
James, G. L., Goldstein, J. L., & Brown, M. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6221 · Cited by 290
Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study
Stiller, C., Chessells, J., & Fitchett, M. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.431 · Cited by 287
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., & Lee, T. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.9141 · Cited by 285
Largaespada, D. A., Brannan, C. I., Jenkins, N. A., & Copeland, N. G. (1996) · Nature Genetics · doi:10.1038/ng0296-137 · Cited by 284
Glomset, J. A., & Farnsworth, C. C. (1994) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.10.110194.001145 · Cited by 280
Schulte, T. W., Blagosklonny, M. V., Romanova, L., Mushinski, J. F., Monia, B. P., Johnston, J. F., Nguyen, P., Trepel, J., & Neckers, L. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5839 · Cited by 269
Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
Cox, A. D., & Der, C. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00011-5 · Cited by 266
Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo.
Gibbs, J. B., Pompliano, D. L., Mosser, S. D., Rands, E., Lingham, R. B., Singh, S. B., Scolnick, E. M., Kohl, N. E., & Oliff, A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52998-7 · Cited by 260
Identification of Ras farnesyltransferase inhibitors by microbial screening.
Hara, M., Akasaka, K., Akinaga, S., Okabe, M., Nakano, H., Gomez, R., Wood, D., Uh, M., & Tamanoi, F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2281 · Cited by 257
The novel activation of ABL by fusion to an ets-related gene, TEL.
Papadopoulos, P., Ridge, S. A., Boucher, C. A., Stocking, C., & Wiedemann, L. M. (1995) · PubMed · Cited by 256
Reversible palmitoylation of signaling proteins
Mumby, S. M. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80056-7 · Cited by 252
Du, W., Lebowitz, P. F., & Prendergast, G. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1831 · Cited by 248
The mechanism of IL-5 signal transduction
Adachi, T., & Alam, R. (1998) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1998.275.3.c623 · Cited by 242
Lerner, E. C., Zhang, T.-T., Knowles, D. B., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201296 · Cited by 239
Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., & Garcia, A. M. (1995) · PubMed · Cited by 238
Molecular cloning and expression of palmitoyl-protein thioesterase.
Camp, L. A., Verkruyse, L. A., Afendis, S. J., Slaughter, C. A., & Hofmann, S. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31641-1 · Cited by 235
Mutations in N-ras predominate in acute myeloid leukemia
Bos, J., Verlaan-de Vries, M., van der Eb, A., Janssen, J., Delwel, R., Lowenberg, B., & Colly, L. (1987) · Blood · doi:10.1182/blood.v69.4.1237.1237 · Cited by 235
The murine N-ras gene is not essential for growth and development.
Umanoff, H., Edelmann, W., Pellicer, A., & Kucherlapati, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1709 · Cited by 234
Sun, J., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1998) · Oncogene · doi:10.1038/sj.onc.1201656 · Cited by 230
Sun, J., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1995) · PubMed · Cited by 227
Janssen, J. W., Steenvoorden, A. C., Lyons, J., Anger, B., Böhlke, J. U., Bos, J. L., Seliger, H., & Bartram, C. R. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9228 · Cited by 225
Yokoyama, K., Goodwin, G. W., Ghomashchi, F., Glomset, J. A., & Gelb, M. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.12.5302 · Cited by 224
Lebowitz, P. F., Davide, J. P., & Prendergast, G. C. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6613 · Cited by 221
Analysis of RAS oncogene mutations in human lymphoid malignancies.
Neri, A., Knowles, D. M., Greco, A., McCormick, F., & Dalla-Favera, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.23.9268 · Cited by 214
RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up
Padua, R., Guinn, B.-A., Al-Sabah, A., Smith, M., Taylor, C., Pettersson, T., Ridge, S., Carter, G., White, D., Oscier, D., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2401044 · Cited by 213
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff, A., Balog, A., Su, D.-S., Danishefsky, S. J., & Rosen, N. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1369 · Cited by 210
Büttner, C., Henz, B. M., Welker, P., Sepp, N. T., & Grabbe, J. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00414.x · Cited by 209
Prendergast, G. C., Davide, J. P., deSolms, S. J., Giuliani, E. A., Graham, S. L., Gibbs, J. B., Oliff, A., & Kohl, N. E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.4193 · Cited by 209
Non-Ras targets of farnesyltransferase inhibitors: focus on Rho
Lebowitz, P. F., & Prendergast, G. C. (1998) · Oncogene · doi:10.1038/sj.onc.1202175 · Cited by 209
Jousset, C., Carron, C., Boureux, A., Quang, C. T., Oury, C., Dusanter‐Fourt, I., Charon, M., Levin, J., Bernard, O., & Ghysdael, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.1.69 · Cited by 207
Evidence for a Ras/Ral signaling cascade
Feig, L. A., Urano, T., & Cantor, S. (1996) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)10058-x · Cited by 207
Saison-Behmoaras, T., Tocqué, B., Rey, I., Chassignol, M., Thuong, N. T., & Hélène, C. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb08051.x · Cited by 199
Zhang, F. L., Kirschmeier, P., Carr, D., James, L., Bond, R. W., Wang, L., Patton, R., Windsor, W. T., Syto, R., Zhang, R., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.15.10232 · Cited by 197
Catling, A. D., Schaeffer, H.-J., Reuter, C. W. M., Reddy, G. R., & Weber, M. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5214 · Cited by 196
Self-citationBernhard, E. J., McKenna, W. G., Hamilton, A. D., Sebti, S. M., Qian, Y., Wu, J., & Muschel, R. J. (1998) · PubMed · Cited by 195
Dislodgment and Accelerated Degradation of Ras
Haklai, R., Weisz, M. G., Elad, G., Paz, A., Marciano, D., Egozi, Y., Ben-Baruch, G., & Kloog, Y. (1998) · Biochemistry · doi:10.1021/bi972032d · Cited by 194
Selective Inhibition of Ras-dependent Cell Growth by Farnesylthiosalisylic Acid
Marom, M., Haklai, R., Ben-Baruch, G., Marciano, D., Egozi, Y., & Kloog, Y. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22263 · Cited by 193
Mechanism of Activation of the GM‐CSF, IL‐3, and IL‐5 Family of Receptors
Guthridge, M. A., Stomski, F. C., Thomas, D., Woodcock, J. M., Bagley, C. J., Berndt, M. C., & Lopez, A. F. (1998) · STEM CELLS · doi:10.1002/stem.160301 · Cited by 192
Vogt, A., Sun, J., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.27224 · Cited by 190
Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA
(1991) · Lung Cancer · doi:10.1016/0169-5002(91)90412-y · Cited by 188
Protein Prenylation, et cetera--Signal Transduction in Two Dimensions
Gelb, M. H. (1997) · Science · doi:10.1126/science.275.5307.1750 · Cited by 186
Lebowitz, P. F., Sakamuro, D., & Prendergast, G. C. (1997) · PubMed · Cited by 181
Jaaro, H., Rubinfeld, H., Hanoch, T., & Seger, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3742 · Cited by 180
Lerner, E. C., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26770 · Cited by 172
Dosil, M., Wang, S., & Lemischka, I. R. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6572 · Cited by 172
Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A., Bearss, D. J., Conner, M. W., et al. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.85 · Cited by 171
Inhibitors of ras farnesyltransferases
Tamanoi, F. (1993) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(93)90072-u · Cited by 170
Kalra, R., Paderanga, D., Olson, K., & Shannon, K. (1994) · Blood · doi:10.1182/blood.v84.10.3435.3435 · Cited by 164
Ras oncogene mutation in multiple myeloma.
Neri, A., Murphy, J. P., Cro, L., Ferrero, D., Tarella, C., Baldini, L., & Dalla-Favera, R. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.5.1715 · Cited by 164
Vogt, A., Qian, Y., McGuire, T. F., Hamilton, A. D., & Sebti, S. M. (1996) · PubMed · Cited by 164
Identification and Characterization of a New Mammalian Mitogen-Activated Protein Kinase Kinase, MKK2
Wu, J., Harrison, J. K., Dent, P., Lynch, K. R., Weber, M. J., & Sturgill, T. W. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.8.4539 · Cited by 161
Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells.
James, G., Goldstein, J. L., & Brown, M. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4454 · Cited by 158
Gelb, M. H., Tamanoi, F., Yokoyama, K., Ghomashchi, F., Esson, K., & Gould, M. N. (1995) · Cancer Letters · doi:10.1016/0304-3835(95)03747-k · Cited by 158
Padua, R. A., Carter, G., Hughes, D. A., Gow, J., Farr, C. J., Oscier, D. G., McCormick, F. P., & Jacobs, A. J. (1988) · PubMed · Cited by 157
Bardwell, L., & Thorner, J. W. (1996) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)30032-7 · Cited by 155
Novel Tricyclic Inhibitors of Farnesyl Protein Transferase
Bishop, W. R., Bond, R. W., Petrin, J., Wang, L., Patton, R., Doll, R. J., Njoroge, G. F., Catino, J. J., Schwartz, J. L., Windsor, W. T., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.51.30611 · Cited by 153
Ras Proteins: Recent Advances and New Functions
Rebollo, A., & Martínez‐A, C. (1999) · Blood · doi:10.1182/blood.v94.9.2971 · Cited by 151
Sulindac sulfide inhibits Ras signaling
Herrmann, C., Block, C., Geisen, C., Haas, K., Weber, C. K., Winde, G., Möröy, T., & Müller, O. (1998) · Oncogene · doi:10.1038/sj.onc.1202085 · Cited by 149
Mangues, R., Corral, T., Kohl, N. E., Symmans, W. F., Lü, S., Malumbres, M., Gibbs, W. W., Oliff, A. I., & Pellicer, À. (1998) · PubMed · Cited by 146
Signaling Networks—Do All Roads Lead to the Same Genes?
Pawson, T. J., & Saxton, T. M. (1999) · Cell · doi:10.1016/s0092-8674(00)80779-5 · Cited by 142
Mutations of the N-ras gene in juvenile chronic myelogenous leukemia
Miyauchi, J., Asada, M., Sasaki, M., Tsunematsu, Y., Kojima, S., & Mizutani, S. (1994) · Blood · doi:10.1182/blood.v83.8.2248.2248 · Cited by 139
Nf1 and Gmcsf Interact in Myeloid Leukemogenesis
Birnbaum, R. A., O'Marcaigh, A. S., Wardak, Z., Zhang, Y., Dranoff, G., Jacks, T., Clapp, D. W., & Shannon, K. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80415-3 · Cited by 138
Pharmaceutical research in molecular oncology
Gibbs, J. (1994) · Cell · doi:10.1016/0092-8674(94)90189-9 · Cited by 132
Elion, E. A. (1998) · Science · doi:10.1126/science.281.5383.1625 · Cited by 131
Manne, V., Yan, N., Jm, C., Av, T., Ricca, C. S., Brown, J. G., Andahazy, M., Schmidt, R. J., Patel, D. V., & Zahler, R. (1995) · PubMed · Cited by 131
Trueblood, C. E., Ohya, Y., & Rine, J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4260-4275.1993 · Cited by 123
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias
Corradini, P., Ladetto, M., Voena, C., Palumbo, A. P., Inghirami, G., Knowles, D., Boccadoro, M., & Pileri, A. (1993) · Blood · doi:10.1182/blood.v81.10.2708.2708 · Cited by 122
Sepp‐Lorenzino, L., & Rosen, N. X. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20243 · Cited by 120
Quilliam, L. A., Castro, A. F., Rogers-Graham, K. S., Martin, C. B., Der, C. J., & Bi, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23850 · Cited by 119
Farnesyl Derivatives of Rigid Carboxylic Acids - Inhibitors of ras-Dependent Cell Growth
Marciano, D., Ben‐Baruch, G., Marom, M., Egozi, Y., Haklai, R., & Kloog, Y. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00008a004 · Cited by 119
Wittinghofer, A. (1998) · PubMed · Cited by 117
McGuire, T. F., Qian, Y., Vogt, A., Hamilton, A. D., & Sebti, S. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27402 · Cited by 115
Biochemical Analysis of MEK Activation in NIH3T3 Fibroblasts
Reuter, C. W., Catling, A. D., Jelı́nek, T., & Weber, M. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7644 · Cited by 114
Self-citationSignaling Pathways Activated by Oncogenic Forms of Abl Tyrosine Kinase
Zou, X., & Calame, K. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18141 · Cited by 114
Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase.
Patriotis, C., Makris, A. M., Chernoff, J., & Tsichlis, P. N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9755 · Cited by 113
R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells.
Cox, A. D., Brtva, T. R., Lowe, D. G., & Der, C. J. (1994) · PubMed · Cited by 111
Marshall, C. J. (1996) · Nature · doi:10.1038/383127a0 · Cited by 109
James, G. L., Brown, M. S., Cobb, M. H., & Goldstein, J. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47043-3 · Cited by 108
Hirsch‐Ginsberg, C., LeMaistre, A., Kantarjian, H. M., Talpaz, M., Cork, A., Freireich, E., Trujillo, J., Lee, M., & Stass, S. A. (1990) · Blood · doi:10.1182/blood.v76.6.1214.1214 · Cited by 106
c‐kit point mutation of extracellular domain in patients with myeloproliferative disorders
Nakata, Y., Kimura, A., Katoh, O., Kawaishi, K., Hyodo, H., Abe, K., Kuramoto, A., & Satow, Y. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05364.x · Cited by 104
Njoroge, F. G., Taveras, A. G., Kelly, J. M., Remiszewski, S., Mallams, A. K., Wolin, R. L., Afonso, A., Cooper, A. B., Rane, D. F., Liu, Y., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980462b · Cited by 102
Dudler, T., & Gelb, M. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11541 · Cited by 100
Mutant N-ras Induces Myeloproliferative Disorders and Apoptosis in Bone Marrow Repopulated Mice
MacKenzie, K. L., Dolnikov, A., Millington, M., Shounan, Y., & Symonds, G. P. (1999) · Blood · doi:10.1182/blood.v93.6.2043.406k17_2043_2056 · Cited by 99
Aberrant Function of the Ras-Related Protein TC21/R-Ras2 Triggers Malignant Transformation
Graham, S. M., Cox, A. D., Drivas, G., Rush, M. G., D’Eustachio, P., & Der, C. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.4108-4115.1994 · Cited by 97
Novel Ras antagonist blocks human melanoma growth
Jansen, B., Schlagbauer‐Wadl, H., Kahr, H., Heere‐Ress, E., Mayer, B. X., Eichler, H.-G., Pehamberger, H., Gana‐Weisz, M., Ben‐David, E., Kloog, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14019 · Cited by 95
Bardwell, L. (1996) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(96)30032-7 · Cited by 95
Liu, L., Dudler, T., & Gelb, M. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23269 · Cited by 93
Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about
Sawyers, C. L., & Denny, C. T. (1994) · Cell · doi:10.1016/0092-8674(94)90307-7 · Cited by 92
Leftheris, K., Kline, T. B., Vite, G. D., Cho, Y. H., Bhide, R. S., Patel, D. V., Patel, M. M., Schmidt, R. J., Weller, H. N., Andahazy, M., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950642a · Cited by 88
In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor onNf1-Deficient Hematopoietic Cells
Mahgoub, N., Taylor, B. R., Gratiot, M., Kohl, N. E., Gibbs, W. W., Jacks, T., & Shannon, K. (1999) · Blood · doi:10.1182/blood.v94.7.2469.419a01_2469_2476 · Cited by 86
Developmentally-regulated expression of murine K-ras isoforms
Pells, S., Divjak, M., Romanowski, P., Impey, H., Hawkins, N. J., Clarke, A. R., Hooper, M. L., & Williamson, D. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201354 · Cited by 83
Tobal, K., Pagliuca, A., Bhatt, B., Bailey, N., Layton, D. M., & Mufti, G. J. (1990) · PubMed · Cited by 83
Nørgaard, P. H., Law, B. K., Joseph, H., Page, D. L., Shyr, Y., Mays, D., Pietenpol, J. A., Kohl, N. E., Oliff, A. I., Coffey, R. J., et al. (1999) · PubMed · Cited by 78
Verheul, H. M. W., Panigrahy, D., Yuan, J., & D’Amato, R. J. (1998) · British Journal of Cancer · doi:10.1038/sj.bjc.6690020 · Cited by 73
Ito, T., Kawata, S., Tamura, S., Igura, T., Nagase, T., Miyagawa, J., Yamazaki, E., Ishiguro, H., & Matsuzawa, Y. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb03146.x · Cited by 71
Emanuel, P. D., Snyder, R. C., Wiley, T. R., Gopurala, B., & Castleberry, R. P. (2000) · Blood · doi:10.1182/blood.v95.2.639 · Cited by 65
Growth and differentiation signals regulated by the M-CSF receptor
Rohrschneider, L. R., Bourette, R. P., Lioubin, M. N., Algate, P. A., Myles, G. M., & Carlberg, K. (1997) · Molecular Reproduction and Development · doi:10.1002/(sici)1098-2795(199701)46:1<96::aid-mrd15>3.0.co;2-1 · Cited by 63
Therapeutic intervention and signaling
Heimbrook, D. C., & Oliff, A. I. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80152-x · Cited by 61
The Ras AntagonistS-Farnesylthiosalicylic Acid Induces Inhibition of MAPK Activation
Gana‐Weisz, M., Haklai, R., Marciano, D., Egozi, Y., Ben‐Baruch, G., & Kloog, Y. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7582 · Cited by 61
Booden, M. A., Baker, T. L., Solski, P. A., Der, C. J., Punke, S. G., & Buss, J. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.3.1423 · Cited by 60
Dalton, M. B., Fantle, K., Bechtold, H. A., DeMaio, L., Evans, R. M., Krystosek, A., & Sinensky, M. S. (1995) · PubMed · Cited by 58
Stringent structural requirements for anti-Ras activity of S-prenyl analogues
Aharonson, Z., Gana‐Weisz, M., Varsano, T., Haklai, R., Marciano, D., & Kloog, Y. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(97)00077-x · Cited by 54
Kainuma, O., Asano, T., Hasegawa, M., et al. (1997) · Pancreas · doi:10.1097/00006676-199711000-00008 · Cited by 53
Williams, D. H., Wilkinson, S. E., Purton, T., Lamont, A. G., Flotow, H., & Murray, E. J. (1998) · Biochemistry · doi:10.1021/bi972914c · Cited by 51
Ras PartnersPreprint
Aelst, L. V., White, M. A., & Wigler, M. H. (1994) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1994.059.01.022 · Cited by 51
Bredel, M., Pollack, I. F., Freund, J. M., Hamilton, A. D., & Sebti, S. M. (1998) · Neurosurgery · doi:10.1097/00006123-199807000-00081 · Cited by 50
Mutation analysis of the N‐ras proto‐oncogene in active and remission phase of human acute leukemias
Senn, H., Trǎn‐Thang, C., Wodnar-Filipowicz, A., Jiricny, J., Fopp, M., Gratwohl, A. A., Signer, E., Weber, W., & Moroni, C. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410112 · Cited by 48
Lantry, L. E. (2000) · Carcinogenesis · doi:10.1093/carcin/21.1.113 · Cited by 47
Prendergast, G. C., Davide, J. P., Lebowitz, P. F., Wechsler‐Reya, R. J., & Kohl, N. E. (1996) · PubMed · Cited by 47
THE MOLECULAR PATHOPHYSIOLOGY OF MYELOID LEUKAEMIAS: Ras REVISITED
Byrne, J., & Marshall (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00554.x · Cited by 43
Nagase, T., Kawata, S., Tamura, S., Matsuda, Y., Inui, Y., Yamasaki, E., Ishiguro, H., Ito, T., Miyagawa, J., Mitsui, H., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.499 · Cited by 42
Yonemoto, M., Satoh, T., Arakawa, H., Suzuki‐Takahashi, I., Monden, Y., Kodera, T., Tanaka, K., Aoyama, T., Iwasawa, Y., Kamei, T., et al. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.1 · Cited by 42
RAS gene mutations in childhood acute myeloid leukemia: A pediatric oncology group study
Vogelstein, B., Civin, C. I., Preisinger, A. C., Krischer, J. P., Steuber, P., Ravindranath, Y., Weinstein, H. J., Elfferich, P., & Bos, J. L. (1990) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870020212 · Cited by 41
Liu, M., Bryant, M., Chen, J., Lee, S., Yaremko, B., Li, Z., Dell, J., Lipari, P., Malkowski, M. G., Prioli, N. A., et al. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050862 · Cited by 41
NMR studies of novel inhibitors bound to farnesyl‐protein transferase
Koblan, K. S., Mosser, S. D., Omer, C. A., Culberson, J. C., DeSolms, S. J., Giuliani, E. A., Pitzenberger, S. M., & Bogusky, M. J. (1995) · Protein Science · doi:10.1002/pro.5560040408 · Cited by 40
Villar, K. D., Urano, J., Guo, L., & Tamanoi, F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.27010 · Cited by 40
ras Proto-Oncogene Activation in Human Malignancy
Clark, G. J., & Der, C. J. (1995) · Humana Press eBooks · doi:10.1007/978-1-4757-2381-6_2 · Cited by 39
Hydroxamic Acid-Based Bisubstrate Analog Inhibitors of Ras Farnesyl Protein Transferase
Patel, D. V., YOUNG, M. G., Robinson, S. P., Hunihan, L. W., Dean, B. J., & Gordon, E. M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960190h · Cited by 37
CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents
Omer, C. A., & Kohl, N. E. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01129-2 · Cited by 35
RAS GENES AND ACUTE MYELOID LEUKAEMIA
Toksoz, D., Farr, C. J., & Marshall, C. J. (1989) · British Journal of Haematology · doi:10.1111/j.1365-2141.1989.tb06265.x · Cited by 35
Lupane Derivatives from Lophopetalum wallichii with Farnesyl Protein Transferase Inhibitory Activity
Sturm, S., Gil, R. R., Chai, H., Ngassapa, O. D., Santisuk, T., Reutrakul, V., Howe, A., Moss, M. L., Besterman, J. M., Yang, S., et al. (1996) · Journal of Natural Products · doi:10.1021/np960370u · Cited by 30
Isolation of Novel Saquayamycins as Inhibitors of Farnesyl-protein Transferase.
Sekizawa, R., IINUMA, H., NAGANAWA, H., HAMADA, M., TAKEUCHI, T., YAMAIZUMI, J., & Umezawa, K. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.487 · Cited by 26
CHEN, Y. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09405.x · Cited by 16
A high frequency of N-RAS oncogene mutations in multiple myeloma.
Tanaka, K., Takechi, M., Asaoku, H., Dohy, H., & Kamada, N. (1992) · PubMed · Cited by 16
Oreganic Acid, a Potent Inhibitor of Ras Farnesyl-Protein Transferase
Silverman, K. C., Jayasuriya, H., Cascales, C., Vilella, D., Bills, G. F., Jenkins, R. G., Singh, S. B., & Lingham, R. B. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6314 · Cited by 14
Actinoplanic acids A and B as novel inhibitors of farnesyl-protein transferase
Silverman, K. C., Cascales, C., Genilloud, O., SIGMUND, J. M., Gartner, S., Koch, G. E., GAGLIARDI, M. M., Heimbuch, B. K., Nallin-Omstead, M., Sanchez, M., et al. (1995) · Applied Microbiology and Biotechnology · doi:10.1007/bf00164762 · Cited by 14
Akopyan, T. N., Couedel, Y., Orłowski, M., Fournié‐Zaluski, M., & Roques, B. P. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1113 · Cited by 12
Tsuda, M., MURAOKA, Y., TAKEUCHI, T., et al. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.1031 · Cited by 10
Cited by
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
Yu, Y., Xie, Y., Cao, L., Yang, L., Yang, M., Lotze, M. T., Zeh, H. J., Kang, R., & Tang, D. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1054549 · Cited by 468
Karp, J. E., Lancet, J. E., Kaufmann, S. H., End, D. W., Wright, J. J., Bol, K., Horak, I., Tidwell, M. L., Liesveld, J., Kottke, T. J., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3361 · Cited by 443
Map kinase signaling pathways and hematologic malignancies
Platanias, L. C. (2003) · Blood · doi:10.1182/blood-2002-12-3647 · Cited by 432
Metadata
- Authors
- Reuter, C. W. M., Morgan, M. A., & Bergmann, L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-09-01
- Volume
- 96
- Issue
- 5
- Pages
- 1655-1669
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W194463696
- Cited by
- 300
- References
- 197
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.